The peer-reviewed study published in Cell shows massive promise for psychiatric treatment BOSTON (April 28, 2021) – Delix Therapeutics, a preclinical biotech company developing novel disease-modifying therapeutics for serious psychiatric and neurological conditions, lauded a study published today in the highly-regarded scientific journal Cell by Delix Co-founder and Chief Scientific Officer…


Previous articleSilo Pharma (SILO) and Zylo Therapeutics, Inc. (ZTI) enter into Joint Venture Agreement to focus on the development of ketamine using ZTI’s Z-pod™ technology for the transdermal time released delivery of therapeutics
Next articleMindset Pharma Announces Positive Preclinical Results of Its Proprietary Next Generation DMT & 5-MeO-DMT Compounds